Longevity medicine is a field in the process of inventing itself — assembling, from the raw material of geroscience, a clinical practice that has outpaced both its evidence base and its regulatory framework. daily-remedy.com/growth-horm…

The SELECT trial's results, published in 2023, established something that the GLP-1 agonist's mechanistic profile had long suggested but clinical evidence had not yet confirmed: daily-remedy.com/glp-1-agoni…

The traditional employer pharmacy benefit structure — select a PBM, sign a contract, delegate formulary management — has not disappeared. daily-remedy.com/carve-outs-…

Mark Cuban's Cost Plus Drugs launched in January 2022 with a proposition simple enough to be disruptive: daily-remedy.com/mark-cuban-…

The legal framework for ERISA fiduciary duty does not distinguish between retirement plans and health plans. daily-remedy.com/the-fiducia…

The self-insured employer is, in theory, the most sophisticated buyer in American healthcare. It bears the full financial risk of its employees daily-remedy.com/self-funded…

Every system generates the consultants it deserves. The pharmaceutical rebate system daily-remedy.com/rebate-aggr…

The Medicaid best price rule is an elegant policy mechanism with an unintended consequence that has become inseparable from its intended effect. daily-remedy.com/medicaids-b…

The idea is simple enough to fit on an index card: instead of manufacturer rebates flowing to pharmacy benefit managers and plan sponsors at the end of a contract period daily-remedy.com/the-deferre…

Call it the rebate wall: the financial barrier that branded pharmaceutical manufacturers have erected around their formulary positions, daily-remedy.com/the-rebate-…

There is a category error embedded in most comparisons of MedPricer and Turquoise Health daily-remedy.com/the-intelli…

The request-for-proposal processes that large health plans run for analytics vendors share a recurring structural problem daily-remedy.com/the-payers-…

Two platforms, two theories of change. That is the cleanest way to frame a comparison between MedPricer and Turquoise Health that resists the temptation to rank them as competitors on a single dimension. daily-remedy.com/two-platfor…

Knowing the terrain and navigating it are different skills — a distinction cartographers have understood for centuries and healthcare market reformers have spent decades obscuring. daily-remedy.com/turquoise-h…

The machine-readable files arrived on schedule, and almost nobody knew what to do with them. daily-remedy.com/the-price-i…

When the FDA declared the semaglutide shortage resolved in February 2025 and the tirzepatide shortage resolved in October 2024, daily-remedy.com/after-the-s…

Casgevy and Lyfgenia, the two FDA-approved gene therapies for sickle cell disease, list at $2.2 million and $3.1 million respectively, administered once. daily-remedy.com/one-dose-ma…

Ask a pharmaceutical executive what their drug costs, and the answer you receive will depend on what the executive wants you to know . daily-remedy.com/the-number-…

Most organizations that consume drug pricing data never question it. daily-remedy.com/the-audit-t…

If a single legislative paragraph could expose the rebate that flows from a manufacturer to a plan sponsor through a pharmacy benefit manager, . daily-remedy.com/pbms-and-th…